Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2020, Vol. 14 Issue (2) : 199-209    https://doi.org/10.1007/s11684-020-0768-7
RESEARCH ARTICLE
Phase- and epidemic region-adjusted estimation of the number of coronavirus disease 2019 cases in China
Ruijie Chang1, Huwen Wang1, Shuxian Zhang1, Zezhou Wang2, Yinqiao Dong3, Lhakpa Tsamlag1, Xiaoyue Yu1, Chen Xu1, Yuelin Yu1, Rusi Long1, Ning-Ning Liu1, Qiao Chu1, Ying Wang1, Gang Xu1, Tian Shen1, Suping Wang1, Xiaobei Deng1, Jinyan Huang4, Xinxin Zhang5(), Hui Wang1(), Yong Cai1()
1. School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2. Department of Cancer Prevention, Shanghai Cancer Center, Fudan University; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200025, China
3. Department of Environmental and Occupational Health, School of Public Health, China Medical University, Shenyang 110122, China
4. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
5. Research Laboratory of Clinical Virology, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital and Ruijin Hospital North Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
 Download: PDF(2246 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

The outbreak of the coronavirus disease 2019 in China was first reported in Wuhan in December 2019 and gradually spread to other areas in China. After implementation of prevention and control measures, the estimation of the epidemic trend is needed. A phase- and region-adjusted SEIR model was applied for modeling and predicting the number of cases in Wuhan, Hubei Province and regions outside Hubei Province in China. The estimated number of infections could reach its peak in late February 2020 in Wuhan and Hubei Province, which is 55 303–84 520 and 83 944–129 312, respectively, while the epidemic peaks in regions outside Hubei Province in China could appear on February 13, 2020 with the estimated 13 035–19 108 cases. According to the estimation, the outbreak would abate in March and April all over China. Current estimation provided evidence for planned work resumption under stringent prevention and control in China to further support the fight against the epidemic. Nevertheless, there is still possibility of the second outbreak brought by the work resumption and population migration, especially from Hubei Province and high intensity cities outside Hubei Province. Strict prevention and control measures still need to be considered in the regions with high intensity of epidemic and densely-populated cities.

Keywords SEIR model      COVID-19      estimate      China     
Corresponding Author(s): Xinxin Zhang,Hui Wang,Yong Cai   
Just Accepted Date: 18 March 2020   Online First Date: 31 March 2020    Issue Date: 09 May 2020
 Cite this article:   
Ruijie Chang,Huwen Wang,Shuxian Zhang, et al. Phase- and epidemic region-adjusted estimation of the number of coronavirus disease 2019 cases in China[J]. Front. Med., 2020, 14(2): 199-209.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-020-0768-7
https://academic.hep.com.cn/fmd/EN/Y2020/V14/I2/199
Fig.1  Phase-adjusted estimation of the number of COVID-19 cases in Wuhan, China (December 1, 2019– April 30, 2020, E= 20I).
Fig.2  Phase-adjusted estimation of the number of COVID-19 cases in Wuhan, China (December 1, 2019–April 30, 2020, E= 30I).
Fig.3  Phase-adjusted estimation of the number of COVID-19 cases in Hubei Province, China (December 1, 2019–April 30, 2020, E= 20I).
Fig.4  Phase-adjusted estimation of the number of COVID-19 cases in Hubei Province, China (December 1, 2019–April 30, 2020, E= 30I).
Fig.5  Phase-adjusted estimation of the number of COVID-19 cases in regions outside Hubei Province, China (January 12, 2020–April 30, 2020, E= 10I, I= 541).
Fig.6  Phase-adjusted estimation of the number of COVID-19 cases in regions outside Hubei Province, China (January 12, 2020– April 30, 2020, E= 10I, I= 793).
Number of deaths Number of cases
Wuhan 2212–5071a 55 303–84 520
Hubei Province 2686–6207b 83 944–129 312
Regions outside ?Hubei Province 91–191c 13 035–19 108
Tab.1  Estimating the number of deaths of COVID-19 cases in China
1 WHO. Pneumonia of unknown cause—China. January 5, 2020.
2 WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). January 30, 2020.
3 National Health Commission of the People’s Republic of China.Update on the incidence of pneumonia with novel coronavirus infection. March 12, 2020. (in Chinese)
4 N Imai, et al.. Report 3: Transmissibility of 2019-nCoV. March 11, 2020.
5 JM Read, JRE Bridgen, DAT Cummings, A, Ho Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. MedRxiv 2020; doi: 10.1101/2020.01.23.20018549
https://doi.org/10.1101/2020.01.23.20018549
6 S Zhao, Q Lin, J Ran, SS Musa, G Yang, W Wang, Y Lou, D Gao, L Yang, D He, MH Wang. Preliminary estimation of the basic reproduction number of novel coronavirus. Int J Infect Dis 2020; 92: 214–217
https://doi.org/10.1016/S0140-6736(20)30260-9 pmid: 32014114
7 H Wang, Z Wang, Y Dong, R Chang, C Xu, X Yu, S Zhang, L Tsamlag, M Shang, J Huang, Y Wang, G Xu, T Shen, X Zhang, Y Cai. Phase-adjusted estimation of the number of coronavirus disease 2019 cases in Wuhan, China. Cell Discov 2020; 6(1): 10
https://doi.org/10.1038/s41421-020-0148-0 pmid: 32133152
8 Q Li, X Guan, P Wu, X Wang, L Zhou, Y Tong, R Ren, KSM Leung, EHY Lau, JY Wong, X Xing, N Xiang, Y Wu, C Li, Q Chen, D Li, T Liu, J Zhao, M Li, W Tu, C Chen, L Jin, R Yang, Q Wang, S Zhou, R Wang, H Liu, Y Luo, Y Liu, G Shao, H Li, Z Tao, Y Yang, Z Deng, B Liu, Z Ma, Y Zhang, G Shi, TTY Lam, JTK Wu, GF Gao, BJ Cowling, B Yang, GM Leung, Z Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29. [Epub ahead of print] doi: 10.1056/NEJMoa2001316
https://doi.org/10.1056/NEJMoa2001316 pmid: 31995857
9 B Tang, X Wang, Q Li, NL Bragazzi, S Tang, Y Xiao, JH Wu. Estimation of the transmission risk of 2019-nCoV and its implication for public health interventions. SSRN 2020 Jan 24. doi: 10.2139/ssrn.3525558
https://doi.org/10.2139/ssrn.3525558
10 C Browne, H Gulbudak, G Webb. Modeling contact tracing in outbreaks with application to Ebola. J Theor Biol 2015; 384: 33–49
https://doi.org/10.1016/j.jtbi.2015.08.004 pmid: 26297316
11 SC Chen, CF Chang, CM Liao. Predictive models of control strategies involved in containing indoor airborne infections. Indoor Air 2006; 16(6): 469–481
https://doi.org/10.1111/j.1600-0668.2006.00443.x pmid: 17100668
12 WHO. Novel coronavirus—China. January 12, 2020.
13 DS Hui, E I Azhar, TA Madani, F Ntoumi, R Kock, O Dar, G Ippolito, TD Mchugh, ZA Memish, C Drosten, A Zumla, E Petersen. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264–266
https://doi.org/10.1016/j.ijid.2020.01.009 pmid: 31953166
14 The Central People’s Government of the People’s Republic of China. Notice on Wuhan novel coronavirus infection of pneumonia epidemic prevention and control. 2020. (in Chinese)
15 National Health Commission of the People’s Republic of China. Full mobilization to contain the epidemic. January 27, 2020. (in Chinese)
16 The Central People’s Government of the People’s Republic of China. Notice on prolonging the Spring Festival Holiday. 2020. (in Chinese)
17 National Health Commission of the People’s Republic of China. Prevention and Control Plan for New Coronavirus-Infected Pneumonia (version 3). January 28, 2020. (in Chinese)
18 The People’s Government of Wuhan. Wuhan Huoshenshan Hospital was completed today. February 2, 2020. (in Chinese)
19 The People’s Government of Hubei Province. Wuhan Leishenshan Hospital welcomed its first confirmed 2019-nCoV patients. February 9, 2020. (in Chinese)
20 National Health Commission of the People’s Republic of China. Do the best to prevent and control the epidemic from the source. February 6, 2020. (in Chinese)
21 Health Commission of Huber Province. Update on 2019-nCoV cases in Hubei Province. February 13, 2020. (in Chinese)
22 H Fang, J Chen, J Hu. Modelling the SARS epidemic by a lattice-based Monte-Carlo simulation. Conf Proc IEEE Eng Med Biol Soc 2005; 2005(7): 7470–7473
pmid: 17282008
23 MM Saito, S Imoto, R Yamaguchi, H Sato, H Nakada, M Kami, S Miyano, T Higuchi. Extension and verification of the SEIR model on the 2009 influenza A (H1N1) pandemic in Japan. Math Biosci 2013; 246(1): 47–54
https://doi.org/10.1016/j.mbs.2013.08.009
24 A Smirnova, L deCamp, G. ChowellForecasting epidemics through nonparametric estimation of time-dependent transmission rates using the SEIR model. Bull Math Biol 2019; 81(11):4343–4365
https://doi.org/10.1007/s11538-017-0284-3 pmid: 28466232
25 WM2 Getz, R Salter, W Mgbara. Adequacy of SEIR models when epidemics have spatial structure: Ebola in Sierra Leone. Philos Trans R Soc Lond B Biol Sci 2019; 374(1775): 20180282
https://doi.org/10.1098/rstb.2018.0282 pmid: 31056043
26 Z Feng, Y Yang, D Xu, P Zhang, MM McCauley, JW Glasser. Timely identification of optimal control strategies for emerging infectious diseases. J Theor Biol 2009; 259(1): 165–171
https://doi.org/10.1016/j.jtbi.2009.03.006 pmid: 19289133
27 CM Peak, LM Childs, YH Grad, CO Buckee. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci USA 2017; 114(15): 4023–4028
https://doi.org/10.1073/pnas.1616438114 pmid: 28351976
28 G Chowell, H Nishiura, L Bettencourt. Comparative estimation of the reproduction number for pandemic influenza from daily case notification data. J R Soc Interface 2007; 4(12): 155–166
https://doi.org/10.1098/rsif.2006.0161 pmid: 17254982
29 G Chowell, NW Hengartner, C Castillo-Chavez, PW Fenimore, JM Hyman. The basic reproductive number of Ebola and the effects of public health measures: the cases of Congo and Uganda. J Theor Biol 2004; 229(1): 119–126
https://doi.org/10.1016/j.jtbi.2004.03.006 pmid: 15178190
30 The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. Notes from the field: an outbreak of NCIP (2019-nCoV) infection in China — Wuhan, Hubei Province, 2019–2020. China CDC Weekly 2020; 2(5):79–80
31 W Guan, Z Ni, Y Hu, W Liang, C Ou, J He, L Liu, H Shan, C Lei, DSC Hui, B Du, L Li, G Zeng, K Yuen, R Chen, C Tang, T Wang, P Chen, J Xiang, S Li, J Wang, Z Liang, Y Peng, L Wei, Y Liu, Y Hu, P Peng, J Wang, J Liu, Z Chen, G Li, Z Zheng, S Qiu, J Luo, C Ye, S, Zhu N Zhong. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020; doi: 2020.02. 06.20020974
https://doi.org/2020.02.06.20020974
32 N Chen, M Zhou, X Dong, J Qu, F Gong, Y Han, Y Qiu, J Wang, Y Liu, Y Wei, Ja Xia, T Yu, X Zhang, L. Zhang Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507–513
https://doi.org/10.1016/S0140-6736(20)30211-7 pmid: 32007143
33 Y Yang, Q Lu, M Liu, Y Wang, A Zhang, N Jalali, N Dean, I Longini, ME Halloran, B Xu, X Zhang, L Wang, W Liu, L Fang. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv 2020; doi: 2020.02.10.20021675
https://doi.org/2020.02.10.20021675
34 The People’s Government of Hubei Province. Pooling high-quality medical resources all over the country to win the battle of preventing and controlling epidemics. February 11, 2020. (in Chinese)
35 The China News Online Service. The number of newly confirmed cases fell for 14 consecutive days in regions outside Hubei Province in China. February 18, 2020. (in Chinese)
36 National Health Commission of the People’s Republic of China.Circular of the General Office of the National Health Commission on strengthening the guidance of epidemic prevention and control during the resumption of work. March 7, 2020.(in Chinese)
37 National Health Commission of the People’s Republic of China.Diagnosis and treatment scheme for COVID-19 (the sixth edition). February 18, 2020. (in Chinese)
[1] Xiaoguang Xu, Wei Zhang, Mingquan Guo, Chenlu Xiao, Ziyu Fu, Shuting Yu, Lu Jiang, Shengyue Wang, Yun Ling, Feng Liu, Yun Tan, Saijuan Chen. Integrated analysis of gut microbiome and host immune responses in COVID-19[J]. Front. Med., 2022, 16(2): 263-275.
[2] Yi Zhang, Haocheng Zhang, Wenhong Zhang. SARS-CoV-2 variants, immune escape, and countermeasures[J]. Front. Med., 2022, 16(2): 196-207.
[3] Yiming Shao, Yingqi Wu, Yi Feng, Wenxin Xu, Feng Xiong, Xinxin Zhang. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic[J]. Front. Med., 2022, 16(2): 185-195.
[4] Wei Zhang, Xiaoguang Xu, Ziyu Fu, Jian Chen, Saijuan Chen, Yun Tan. PathogenTrack and Yeskit: tools for identifying intracellular pathogens from single-cell RNA-sequencing datasets as illustrated by application to COVID-19[J]. Front. Med., 2022, 16(2): 251-262.
[5] Qiaoli Shi, Fei Xia, Qixin Wang, Fulong Liao, Qiuyan Guo, Chengchao Xu, Jigang Wang. Discovery and repurposing of artemisinin[J]. Front. Med., 2022, 16(1): 1-9.
[6] Jing Wang, Zequn Lu, Meng Jin, Ying Wang, Kunming Tian, Jun Xiao, Yimin Cai, Yanan Wang, Xu Zhang, Tao Chen, Zhi Yao, Chunguang Yang, Renli Deng, Qiang Zhong, Xiongbo Deng, Xin Chen, Xiang-ping Yang, Gonghong Wei, Zhihua Wang, Jianbo Tian, Xiao-ping Chen. Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study[J]. Front. Med., 2022, 16(1): 111-125.
[7] Huai-yu Wang, Suyuan Peng, Zhanghui Ye, Pengfei Li, Qing Li, Xuanyu Shi, Rui Zeng, Ying Yao, Fan He, Junhua Li, Liu Liu, Shuwang Ge, Xianjun Ke, Zhibin Zhou, Gang Xu, Ming-hui Zhao, Haibo Wang, Luxia Zhang, Erdan Dong. Renin--angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension[J]. Front. Med., 2022, 16(1): 102-110.
[8] Zehong Huang, Yingying Su, Tianying Zhang, Ningshao Xia. A review of the safety and efficacy of current COVID-19 vaccines[J]. Front. Med., 2022, 16(1): 39-55.
[9] Yuntao Zhang, Yunkai Yang, Niu Qiao, Xuewei Wang, Ling Ding, Xiujuan Zhu, Yu Liang, Zibo Han, Feng Liu, Xinxin Zhang, Xiaoming Yang. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults[J]. Front. Med., 2022, 16(1): 93-101.
[10] Jianhai Yin, Mei Li, He Yan, Shuisen Zhou, Zhigui Xia. Laboratory diagnosis for malaria in the elimination phase in China: efforts and challenges[J]. Front. Med., 2022, 16(1): 10-16.
[11] Fang Huang, Yanwen Cui, He Yan, Hui Liu, Xiangrui Guo, Guangze Wang, Shuisen Zhou, Zhigui Xia. Prevalence of antifolate drug resistance markers in Plasmodium vivax in China[J]. Front. Med., 2022, 16(1): 83-92.
[12] Li Ni, Zheng Wen, Xiaowen Hu, Wei Tang, Haisheng Wang, Ling Zhou, Lujin Wu, Hong Wang, Chang Xu, Xizhen Xu, Zhichao Xiao, Zongzhe Li, Chene Li, Yujian Liu, Jialin Duan, Chen Chen, Dan Li, Runhua Zhang, Jinliang Li, Yongxiang Yi, Wei Huang, Yanyan Chen, Jianping Zhao, Jianping Zuo, Jianping Weng, Hualiang Jiang, Dao Wen Wang. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial[J]. Front. Med., 2021, 15(5): 704-717.
[13] Weijian Hang, Chen Chen, Xin A. Zhang, Dao Wen Wang. Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2[J]. Front. Med., 2021, 15(4): 638-643.
[14] Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections[J]. Front. Med., 2021, 15(4): 644-648.
[15] Dongsheng Wang, Binqing Fu, Zhen Peng, Dongliang Yang, Mingfeng Han, Min Li, Yun Yang, Tianjun Yang, Liangye Sun, Wei Li, Wei Shi, Xin Yao, Yan Ma, Fei Xu, Xiaojing Wang, Jun Chen, Daqing Xia, Yubei Sun, Lin Dong, Jumei Wang, Xiaoyu Zhu, Min Zhang, Yonggang Zhou, Aijun Pan, Xiaowen Hu, Xiaodong Mei, Haiming Wei, Xiaoling Xu. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial[J]. Front. Med., 2021, 15(3): 486-494.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed